Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiac Safety Study of Evofosfamide in Advanced Solid Tumors
NCT02020226Phase 1Unknown
- Sponsor
- Threshold Pharmaceuticals
- Start
- Nov 2013
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of evofosfamide in solid tumor, sponsored by Threshold Pharmaceuticals. Primary endpoint: Potential for QT/QTc interval prolongation at 2 years. Status: unknown.
02
Drugs
evofosfamide
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02020226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02020226.